Evaxion Biotech A/S (NASDAQ:EVAX) Coverage Initiated by Analysts at HC Wainwright

HC Wainwright began coverage on shares of Evaxion Biotech A/S (NASDAQ:EVAXFree Report) in a research report released on Monday, Marketbeat.com reports. The brokerage issued a buy rating and a $14.00 price target on the stock.

Separately, LADENBURG THALM/SH SH reiterated a neutral rating on shares of Evaxion Biotech A/S in a research note on Thursday, December 21st.

View Our Latest Stock Report on EVAX

Evaxion Biotech A/S Price Performance

EVAX stock opened at $4.21 on Monday. The firm has a market cap of $15.96 million and a P/E ratio of -0.44. The company has a debt-to-equity ratio of 3.95, a quick ratio of 2.81 and a current ratio of 2.81. Evaxion Biotech A/S has a 1 year low of $3.36 and a 1 year high of $18.50. The stock has a 50-day simple moving average of $6.58 and a 200-day simple moving average of $8.00.

Evaxion Biotech A/S (NASDAQ:EVAXGet Free Report) last issued its quarterly earnings data on Tuesday, December 19th. The company reported ($2.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.90) by ($0.20). On average, equities analysts predict that Evaxion Biotech A/S will post -8.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Evaxion Biotech A/S

Several large investors have recently modified their holdings of the stock. Susquehanna International Group LLP raised its stake in Evaxion Biotech A/S by 185.4% during the first quarter. Susquehanna International Group LLP now owns 118,722 shares of the company’s stock worth $134,000 after acquiring an additional 77,122 shares during the period. AE Wealth Management LLC bought a new stake in shares of Evaxion Biotech A/S in the 3rd quarter worth approximately $41,000. Beacon Capital Management LLC lifted its stake in Evaxion Biotech A/S by 606.8% in the fourth quarter. Beacon Capital Management LLC now owns 48,633 shares of the company’s stock valued at $33,000 after buying an additional 41,752 shares during the last quarter. Finally, JPMorgan Chase & Co. bought a new position in shares of Evaxion Biotech A/S during the second quarter worth about $38,000. Institutional investors own 0.58% of the company’s stock.

Evaxion Biotech A/S Company Profile

(Get Free Report)

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers.

Featured Articles

Receive News & Ratings for Evaxion Biotech A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion Biotech A/S and related companies with MarketBeat.com's FREE daily email newsletter.